Top Page
Intelligent Bio Solutions
(NASDAQ:INBS)
Intelligent Bio Solutions (INBS) vs. S&P 500 (SPY)
Intelligent Bio Solutions Business Overview & Revenue Model
Intelligent Bio Solutions Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 3.03M | 3.11M | 1.26M | 0.00 | 1.98M | 188.74K | Gross Profit |
| 1.25M | 1.43M | 326.67K | 0.00 | 1.98M | 188.74K | EBIT |
| -10.84M | -10.28M | -12.60M | -8.34M | -5.57M | -2.71M | EBITDA |
| -10.10M | -8.81M | -9.47M | 30.82K | -1.82M | -561.19K | Net Income Common Stockholders |
| -10.69M | -10.16M | -10.63M | -8.31M | -7.04M | -3.16M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.12M | 6.30M | 1.54M | 8.24M | 12.57M | 427.27K | Total Assets |
| 8.83M | 13.78M | 10.35M | 12.35M | 20.40M | 2.48M | Total Debt |
| 1.08M | 871.44K | 1.34M | 0.00 | 0.00 | 5.13M | Net Debt |
| -38.04K | -5.43M | -201.56K | -8.24M | -12.57M | 4.71M | Total Liabilities |
| 5.67M | 5.60M | 6.67M | 5.81M | 6.85M | 7.69M | Stockholders Equity |
| 3.28M | 8.33M | 3.80M | 6.62M | 13.61M | -5.19M |
| Cash Flow | Free Cash Flow | ||||
| -7.82M | -9.79M | -7.88M | -3.74M | -11.30M | -498.62K | Operating Cash Flow |
| -10.12M | -9.57M | -7.38M | -3.36M | -11.30M | -498.62K | Investing Cash Flow |
| -176.24K | -221.43K | -694.14K | -880.22K | 0.00 | -14.00K | Financing Cash Flow |
| 11.50M | 14.56M | 1.44M | 0.00 | 23.40M | 733.86K |
Intelligent Bio Solutions Technical Analysis
Intelligent Bio Solutions Risk Analysis
Intelligent Bio Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.93B | ― | -19.42% | ― | 56.75% | 59.77% | |
68 Neutral | $1.02B | 18.09 | 19.46% | ― | 19.07% | ― | |
60 Neutral | $14.78M | ― | -279.80% | ― | 23.21% | 57.43% | |
53 Neutral | $8.52B | ― | -37.09% | ― | 10.37% | -389.98% | |
49 Neutral | $13.39B | ― | -30.11% | ― | -2.93% | -4.69% | |
49 Neutral | $6.90B | 0.02 | -54.05% | 2.46% | 24.91% | -3.14% | |
46 Neutral | $2.52B | ― | -50.74% | ― | -7.03% | -20233.78% |
Intelligent Bio Solutions Corporate Events
On February 10, 2025, Intelligent Bio Solutions Inc. announced its 2024 growth achievements and its strategic plan to enter the U.S. market in 2025. In 2024, the company achieved significant revenue growth of 148% year-over-year, driven by the strong adoption of its drug screening technology. The company completed its FDA 510(k) pre-market notification in December, positioning itself to enter the U.S. drug screening market, which represents a large portion of the global demand. Rising drug positivity rates and increased safety regulations underscore the need for the company’s non-invasive testing solutions. The company anticipates continued growth, focusing on safety-critical industries and leveraging its expanding global customer base.
On February 7, 2025, Intelligent Bio Solutions announced that Avon Freight Group has adopted its non-invasive Intelligent Fingerprinting Drug Testing Solution for random drug testing at its UK sites. This move by Avon, a significant logistics firm, highlights a shift towards more respectful and efficient drug testing methods, boosting workplace safety and culture. This partnership expands INBS’s network to over 400 accounts in 19 countries, reinforcing its industry leadership as the UK drug testing market is projected to reach $453 million by 2030. The company’s strategic growth, including a planned U.S. expansion following an FDA submission, positions it to address growing demand for scalable and cost-effective drug testing solutions.
On January 31, 2025, Intelligent Bio Solutions announced plans to upgrade its Intelligent Fingerprinting Drug Screening System with multilingual capabilities, enhancing accessibility for over 4 billion users globally. This strategic move supports the company’s international expansion and aligns with its 2025 entry into the US market, tapping into the growing demand for workplace drug testing solutions projected to reach $8 billion by 2030.
On January 29, 2025, Intelligent Bio Solutions Inc. announced that Quantum Traffic Management, a UK-based traffic management provider, adopted their Intelligent Fingerprinting Drug Testing Solution across ten sites to enhance workplace testing efficiency and safety. This transition from traditional saliva and urine testing to INBS’s rapid, non-invasive system marks a significant operational improvement for Quantum TM, and underscores INBS’s growing influence in the drug screening market, with over 400 accounts globally and plans to enter the US market in 2025.
On January 28, 2025, Intelligent Bio Solutions announced a significant partnership with IVY Diagnostics to expand its Intelligent Fingerprinting Drug Testing Solution in Europe and the Middle East. This collaboration is strategic due to the projected growth of the drug screening market in these regions, with Europe expected to reach $3.6 billion by 2030. IVY Diagnostics, leveraging its extensive network and expertise, will help INBS capture new opportunities, particularly in drug rehabilitation and law enforcement, with ongoing trials in Italy. This partnership positions the company to effectively meet the rising demand for efficient drug screening solutions.
Intelligent Bio Solutions Inc. has submitted a 510(k) premarket notification to the FDA for its Intelligent Fingerprinting Drug Screening System, a non-invasive and rapid drug testing method. This submission marks a significant step toward entering the US market, offering opportunities for growth and establishing the company as a leader in non-invasive testing solutions across various industries.